Psychological Symptoms and Self-Medication Behavior among COVID-19 Recoverees
,
Abstract
Objective: The COVID-19 pandemic has led to a surge in psychological symptoms, even after recovery. However, the measurement of psychiatric disorders requires diagnostic tools, whereas most studies, including this one, use symptom-based screening instruments. This study aimed to assess the prevalence of depressive symptoms and levels of emotional distress (stress and anxiety) among COVID-19 recoverees. It also examined the prevalence and predictors of self-medication behaviors in this population.
Method: A cross-sectional study was conducted among 400 adults who had recovered from COVID-19 and attended academic pharmacies in Isfahan, Iran. Data were collected using the Patient Health Questionnaire-9 (PHQ-9) for depressive symptoms, Depression Anxiety Stress Scales-21 (DASS-21) for emotional distress, and a researcher-designed questionnaire to assess self-medication practices. Logistic regression was performed to identify predictors of self-medication.
Results: Moderate to severe depressive symptoms (PHQ-9 ≥ 10) were reported in 35.1% of participants. Based on DASS-21 scores, 38.8% had moderate to severe anxiety, and 33.5% had moderate to severe stress. Self-medication was reported by 32.8% of participants, primarily using sedatives, antidepressants, and herbal remedies. Depression was significantly associated with self-medication (OR = 2.18; 95% CI: 1.45–3.29; P < 0.001), while anxiety and stress were not.
Conclusion: This study highlights a high prevalence of psychological symptomatology and self-medication among individuals recovering from COVID-19. Since only depressive symptoms were assessed using a validated psychiatric screening tool (PHQ-9), and no formal diagnostic criteria were applied, the results should not be interpreted as reflecting psychiatric disorder prevalence. The findings underscore the need for improved mental health support and regulation of medication access in post-COVID care settings.
2. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 Syndrome: The Persistent Symptoms at the Post-viral Stage of the Disease. A Systematic Review of the Current Data. Front Med (Lausanne). 2021;8:653516.
3. Shanbehzadeh S, Tavahomi M, Zanjari N, Ebrahimi-Takamjani I, Amiri-Arimi S. Physical and mental health complications post-COVID-19: Scoping review. J Psychosom Res. 2021;147:110525.
4. Pierce JD, Shen Q, Cintron SA, Hiebert JB. Post-COVID-19 Syndrome. Nurs Res. 2022;71(2):164-74.
5. Bennadi D. Self-medication: A current challenge. J Basic Clin Pharm. 2013;5(1):19-23.
6. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611-27.
7. Malik M, Tahir MJ, Jabbar R, Ahmed A, Hussain R. Self-medication during Covid-19 pandemic: challenges and opportunities. Drugs Ther Perspect. 2020;36(12):565-7.
8. Shrestha AB, Aryal M, Magar JR, Shrestha S, Hossainy L, Rimti FH. The scenario of self-medication practices during the covid-19 pandemic; a systematic review. Ann Med Surg (Lond). 2022;82:104482.
9. Mohammadi SM, Ashtari S, Khosh Fetrat M. The psychological impact of COVID-19 pandemic on mental health of Iranian population. Int J Travel Med Glob Health. 2021;9(1):19-24.
10. Sahebi A, Asghari MJ, Salari RS. Validation of depression anxiety and stress scale (DASS-21) for an Iranian population. 2005.
11. Dadfar M, Asgharnejadfarid AA, Hosseini AF, Esfahani MN, Lester D, Kalibatseva Z. Measuring somatic symptoms with the PHQ-15: A comparative study of three Iranian samples. Mental health, religion & culture. 2020;23(3-4):289-301.
12. de Souza CM, Hidalgo MP. World Health Organization 5-item well-being index: validation of the Brazilian Portuguese version. Eur Arch Psychiatry Clin Neurosci. 2012;262(3):239-44.
13. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594-600.
14. Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8(5):416-27.
15. Azami-Aghdash S, Mohseni M, Etemadi M, Royani S, Moosavi A, Nakhaee M. Prevalence and Cause of Self-Medication in Iran: A Systematic Review and Meta-Analysis Article. Iran J Public Health. 2015;44(12):1580-93.
16. Yasmin F, Asghar MS, Naeem U, Najeeb H, Nauman H, Ahsan MN, et al. Self-Medication Practices in Medical Students During the COVID-19 Pandemic: A Cross-Sectional Analysis. Front Public Health. 2022;10:803937.
17. Amuzie CI, Kalu KU, Izuka M, Nwamoh UN, Emma-Ukaegbu U, Odini F, et al. Prevalence, pattern and predictors of self-medication for COVID-19 among residents in Umuahia, Abia State, Southeast Nigeria: policy and public health implications. J Pharm Policy Pract. 2022;15(1):34.
18. Kazemioula G, Golestani S, Alavi SMA, Taheri F, Gheshlagh RG, Lotfalizadeh MH. Prevalence of self-medication during COVID-19 pandemic: A systematic review and meta-analysis. Front Public Health. 2022;10:1041695.
| Files | ||
| Issue | Vol 20 No 3 (2025) | |
| Section | Original Article(s) | |
| Keywords | ||
| Community Pharmacy Depression Emotional Distress Iran Post-COVID-19 Syndrome Self-Medication | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
